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ABSTRACT 
D-Myo-inositol 1,2,6-triphosphate (alpha trinositol, AT) has been shown to 
attenuate muscle atrophy in a murine cachexia model through an increase in protein 
synthesis and a decrease in degradation.  The mechanism of this effect has been 
investigated in murine myotubes using a range of catabolic stimuli, including 
proteolysis-inducing factor (PIF), angiotensin II (Ang II), lipopolysaccharide, and 
tumour necrosis factor- / interferon-.  At a concentration of 100M AT was found 
to attenuate both the induction of protein degradation and depression of protein 
synthesis in response to all stimuli.  The effect on protein degradation was 
accompanied by attenuation of the increased expression and activity of the ubiquitin-
proteasome pathway.  This suggests that AT inhibits a signalling step common to all 
four agents.  This target has been shown to be activation (autophosphorylation) of the 
dsRNA-dependent protein kinase (PKR) and the subsequent phosphorylation of 
eukaryotic initiation factor 2 on the -subunit, together with downstream signalling 
pathways leading to protein degradation.  AT also inhibited activation of caspase-3/-8, 
which is thought to lead to activation of PKR.  The mechanism of this effect may be 
related to the ability of AT to chelate divalent metal ions, since the attenuation of the 
increased activity of the ubiquitin-proteasome pathway by PIF and Ang II, as well as 
the depression of protein synthesis by PIF, were reversed by increasing concentrations 
of Zn2+.  The ability of AT to attenuate muscle atrophy by a range of stimuli suggests 
that it may be effective in several conditions. 
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1. Introduction 
A number of chronic and end-stage diseases including cancer, chronic heart 
failure (CHF), chronic obstructive pulmonary disease (COPD), sepsis and end-stage 
renal failure are associated with muscle atrophy, leading to weakness and eventually 
death [1].  For muscle atrophy to occur protein degradation must exceed protein 
synthesis, but usually there is an increase in protein degradation together with a 
depression of protein synthesis.  A number of agents have been shown to induce 
muscle atrophy including proteolysis-inducing factor (PIF) [2], angiotensin II (Ang II) 
[3], tumour necrosis factor- [4] and lipopolysaccharide (LPS) [5].  These agents 
cause a depression of protein synthesis in skeletal muscle, as well as an increase in 
protein degradation, and recent results suggest that they all work through the same 
cellular signalling pathway to induce muscle atrophy.  Thus the depression of protein 
synthesis induced by PIF [6], Ang II, TNF- and LPS [7] has been attributed to 
activation of the dsRNA-dependent protein (PKR), with subsequent phosphorylation 
of eukaryotic initiation factor 2 (eIF2) on the -subunit.  This blocks translation 
initiation by inhibiting binding of initiator methionyl tRNA to the 40S ribosomal 
subunit [8].  They also increase phosphorylation of the elongation factor (eEF2), 
decreasing its affinity for the ribosome and contributing to the depression of global 
protein synthesis [9]. 
The predominant pathway responsible for protein degradation in muscle in a 
range of catabolic conditions is the ubiquitin proteolytic pathway [10].  There is 
increased expression of this pathway in response to PIF [6], Ang II, TNF- [11] and 
LPS [5], mediated by activation of PKR leading to increased formation of reactive 
oxygen species (ROS), via activation of p38 mitogen-activated protein kinase 
(p38MAPK) [11].  The increased ROS leads to activation of nuclear factor-B (NF-
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B), which is responsible for increased expression of proteasome subunits and the 
ubiquitin ligase MuRF1 [12].  Activation (autophosphorylation) of PKR was shown to 
occur through an increase in activity of caspases-3 and -8 [11].  Caspases-3, -7, and -8 
have been reported [13] to cleave PKR at Asp251, releasing the kinase domain from 
the control of the regulatory amino-terminal domain leading to autophosphorylation. 
We have recently identified a polyanionic metal binding agent D-myo-
inositol-1,2,6-triphosphate (alpha trinositol, AT) which attenuated muscle atrophy in 
mice bearing a cachexia-inducing tumour [14].  Muscle mass increased due to an 
increase in protein synthesis and a decrease in protein degradation.  The decrease in 
protein degradation was associated with a decrease in activity of both the ubiquitin-
proteasome pathway and caspase-3 and -8, while protein synthesis was increased due 
to reduced phosphorylation of both PKR and eIF2.  In vitro studies also showed AT 
to attenuate the increased protein degradation in murine myotubes in response to PIF 
and Ang II. 
The current study investigates the mechanism of this effect, as well as protein 
degradation induced by TNF- and LPS and the ability of AT to attenuate the 
depression of protein synthesis induced by PIF, Ang II, TNF- and LPS. 
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2. Materials and Methods 
2.1 Materials Foetal calf serum (FCS), horse serum (HS) and Dulbecco’s modified 
Eagle’s medium (DMEM) were purchased from Invitrogen (Paisley, UK).  L-[2,6-3H] 
Phenylalanine (sp.act.2.2TBq/mmole) was purchased from American Radiochemicals 
(Cardiff, UK).  Hybond A nitrocellulose membranes, and ECL development kits were 
from Amersham Biosciences Ltd (Bucks, UK).  Mouse monoclonal antibodies to 20S 
proteasome -subunits and p42 were from Affiniti Research Products (Exeter, UK).  
Rabbit monoclonal antibodies to phospho and total PKR were purchased from New 
England Biolabs (Herts, UK).  Rabbit polyclonal antisera to phospho eIF2 (Ser51) 
and to total eIF2 was from Santa Cruz Biotechnology (CA).  Rabbit polyclonal 
antisera to myosin heavy chain was from Novocastra (Newcastle, UK).  Rabbit 
polyclonal antisera to mouse -actin, LPS from Ecoli O111:B4, TNF-, IFN-, Ang 
II, the chymotrypsin substrate succinyl LLVY-7-amino-4-methylcoumarin (LLVY-
AMC) and dichlorodihydrofluorescein diacetate, were purchased from Sigma 
Aldridge (Dorset, UK).  Peroxidase-conjugated rabbit anti-mouse antibody and 
peroxidase-conjugated goat anti-rabbit antibody were purchased from Dako Ltd 
(Cambridge, UK).  Electrophoretic mobility shift assay (EMSA) kits were from 
Panomics (Redwood City, CA).  1-D-Myo-inositol 1,2,6-triphosphate (alpha 
trinositol, AT) was supplied by Bioneris (Helsinki, Finland).  Phosphosafe™ 
extraction reagent and rabbit polyclonal antisera to mouse PKC was from Merck 
Eurolab Ltd (Leicestershire, UK).  The caspase-3 and -8 substrates and inhibitors 
were purchased from Biomol International (Devon, UK).  PIF was purified from solid 
MAC16 tumours using affinity chromatography with an anti-PIF monoclonal 
antibody as previously described [15]. 
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2.2 Myogenic cell culture C2C12 myoblasts were routinely propagated in DMEM 
supplemented with 10% FCS, glutamine and 1% penicillin-streptomycin under an 
atmosphere of 10% CO2 in air at 37°C.  When the myoblasts reached confluence they 
were allowed to differentiate into myotubes by replacing the growth medium with 
DMEM containing 2% HS, with media changes every two days.  Differentiation was 
complete within 3 to 5 days and the myotubes were used for experimentation within a 
4 day period. 
 
2.3 Measurement of protein synthesis and degradation in myotubes Experiments were 
carried out on myotubes formed in 6-well multiwell dishes, as described previously 
[6].  Briefly for protein degradation myotubes were labelled with L-[2,6-3H] 
phenylalanine for 24h prior to experimentation, washed extensively, and chased for 2h 
in fresh DMEM without phenol red, to allow degradation of short-lived proteins.  The 
myotubes were then incubated with either PIF or Ang II, at the concentrations and 
additions detailed in the figure legends, for 24h in the presence of excess (2mM) 
phenylalanine, to prevent reincorporation of radioactivity.  The extent of protein 
degradation was determined from the radioactivity released into the medium, as a 
fraction of the total radioactivity incorporated into the myotubes.  Protein synthesis 
was determined by the incorporation of L-[2,6-3H] phenylalanine into myotubes over 
a 4h period in the presence of the additions described in the figure legends.  Protein 
synthesis was calculated as the radioactivity incorporated into acid (0.2M perchloric 
acid) insoluble material. 
 
2.4 Measurement of proteasome activity Functional 20S proteasome activity was 
determined as the “chymotrypsin-like” enzyme activity by the release of 7-amino-4-
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methylcoumarin (AMC) from the fluorogenic peptide succinyl-LLVY-7-AMC as 
described by Orino et al [16].  We have previously described the method in detail for 
murine myotubes [17].  Activity was measured in the absence and presence of the 
specific proteasome inhibitor lactacystin (10M).  Only lactacystin suppressible 
activity was considered to be proteasome specific. 
 
2.5 Caspase activity The activity of caspase 3 was determined by the relase of AMC 
from the specific substrate AcDEVD-AMC in the presence or absence of the caspase 
3 inhibitor AcDEVD-CHO, as described [11].  Myotubes were homogenised in lysis 
buffer (150mmol/L NaCl, 1% NP40, 50mmol/L Tris HCl, pH7.4, 0.25% sodium 
deoxycholate, 2mmol/L EGTA, 1mmol/EDTA, 0.2mmol/L sodium orthovanadate, 
20mmol/L NaF and 1% proteasome inhibitor mixture), left at 4°C, and then room 
temperature for 10min, followed by centrifugation at 15,000g for 15 min. The 
supernatant (50g protein) was incubated with the caspase 3 substrate for 1h, and the 
increase in fluorescence due to AMC was determined at an excitation wavelength of 
370nm and an emission wavelength of 430nm.  The difference in values in the 
absence and presence of the caspase-3 inhibitor was a measure of activity.  The 
method for caspase 8 was similar with the substrate being Z-IEFTD-AFC and the 
inhibitor IETD-CHO.  The increase in fluorescence due to the release of 7-amino-4-
trifluoro-methylcoumarin (AFC) was measured with an excitation wavelength of 
400nm and an emission wavelength of 505nm. 
 
2.6 Measurement of ROS formation in myotubes The method has previously been 
described in detail [18], and measures the conversion of the cell-permeable probe 2,7-
dichlorodihydrofluorescein diacetate, to 2,7-dichlorofluorescein upon oxidation by 
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ROS.  Myotubes were incubated with PIF for 30min, washed with PBS and sonicated 
at 4°C after scraping from the plate.  An aliquot of the supernatant formed by 
centrifugation at 2800g was read on a fluorimeter at an excitation wavelength of 
480nm and an emission wavelength of 510nm.  In all experiments the protein 
concentration of the samples was determined using the Bio-Rad reagent. 
 
2.7 Western blot analysis After the treatments as described in the figure legends, 
myotubes were sonicated in Phosphosafe™ Extraction Reagent and centrifuged at 
18000g for 5 min.  Samples of cytosolic protein (10-15g) were resolved on 10% 
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (6% for 
eIF2) at 180V for approximately 1h.  The protein on the gels was then transferred to 
0.45m nitrocellulose membranes, which were then blocked with 5% Marvel in Tris-
buffered saline, pH 7.5, at 4°C overnight.  The primary antibodies were used at a 
dilution of 1:1000, except for eIF2 (1:500), actin (1:200) and myosin (1:100).  The 
secondary antibodies were used at a dilution of 1:1000.  Incubation was either for 1h 
at room temperature, or overnight, and development was by ECL.  Blots were scanned 
by a densitometer to quantitate differences. 
 
2.8 Electrophoretic mobility shift assay (EMSA) DNA binding proteins were 
extracted from myotube nuclei by hypotonic lysis, followed by high salt extraction as 
described [19].  The EMSA binding assay was carried out using a Panomics EMSA 
“gel shift” kit according to the manufacturer’s instructions.  Assays were conducted 
using a biotin labelled double-stranded oligonucleotide having a consensus 
recognition sequence for NF-B (5’AGTTGAGGGGACTTTCCCAGGC3’).  
Unlabeled probe was added to negative controls, while a positive probe was also 
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supplied by the manufacturer.  Protein-DNA complexes were separated using 
nondenaturing PAGE. 
 
2.9 Statistical analysis All results are shown as mean  S.E. for at least three replicate 
experiments.  Differences in means between groups were determined by one-way 
analysis of variance followed by Tukey-Kramer multiple comparison test.  p values 
less than 0.05 were considered ‘significant’. 
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3. Results 
The effect of AT on total protein degradation in murine myotubes induced by 
LPS over a 24h period is shown in Fig. 1A.  LPS produced a dose-dependent increase 
in protein degradation at concentrations up to 100ng/ml, and this was completely 
attenuated by AT (100M), at all concentrations of LPS.  LPS induced an increase in 
expression of both the 20S proteasome, -subunits and p42, an ATPase subunit of the 
19S regulator, at the same concentrations as that inducing protein degradation (Fig. 
1B), suggesting that it was mediated through the ubiquitin-proteasome pathway.  The 
increase in expression of both the 20S proteasome and p42 in response to LPS was 
completely attenuated by AT, although basal levels were not affected (Fig. 1B).  LPS 
also depressed protein synthesis in myotubes by 50-60% at the same concentrations as 
that inducing protein degradation, and this was also completely attenuated by AT 
(Fig. 1C). 
TNF- (50ng/ml) either alone, or in combination with interferon-g (IFN-; 
10ng/ml), also induced protein degradation in myotubes over a 24h period, and this 
was also completely attenuated by AT down to basal levels (Fig. 2A).  TNF- alone 
produced a 40% decrease in protein synthesis in myotubes after 2h incubation, and 
this was increased up to 60% depression in the presence of IFN-.  Treatment with 
AT, not only attenuated the depression of protein synthesis by TNF- or TNF-+ 
IFN-, but also caused a significant increase in protein synthesis above basal levels 
(Fig. 2B). 
We have previously shown [14] that protein degradation in myotubes in 
response to PIF and Ang II was also attenuated by AT.  Protein degradation induced 
by PIF and Ang II is also mediated by the ubiquitin-proteasome pathway, and both 
induced an increase in proteasome functional activity, as measured by the 
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‘chymotrypsin-like’ enzyme activity (Fig. 3A and B).  As with total protein 
degradation, the induction of ‘chymotrypsin-like’ enzyme activity by PIF and Ang II 
was attenuated by AT, suggesting inhibition of the ubiquitin-proteasome pathway.  
This was confirmed by measurement of expression of the 20S proteasome -subunits 
(Fig. 3C) and p42 (Fig. 3D), which were increased in the presence of PIF and 
completely attenuated by AT.  These results show that AT attenuates protein 
degradation induced by LPS, TNF-, PIF and Ang II by down-regulation of the 
increased expression of the ubiquitin-proteasome pathway.  It also suggests that AT 
inhibits a common mechanism linking protein synthesis and degradation in skeletal 
muscle. 
One potential target is the activation (autophosphorylation) of PKR and the 
subsequent phosphorylation of eIF2 on the -subunit [6].  The immunoblots in Fig. 4 
show that PIF induced phosphorylation of both PKR (Fig. 4A) and eIF2 (Fig. 4B), 
and that this was maximal at the same concentration (4.2nM) as that inducing 
proteasome activity (Fig. 3A), and was completely attenuated by AT.  Other 
signalling pathways activated by PIF and leading to protein degradation including 
activation of protein kinase C (PKC) (Fig. 5A) [20], formation of ROS (Fig. 5B) [18], 
and nuclear accumulation of NF-B (Fig. 5C) [21], were all attenuated by AT.  Since 
these pathways are thought to be downstream of PKR [11], this suggests that AT 
inhibits a signalling pathway upstream of PKR.  One possible candidate could be 
activation of caspase-3/-8, which has been shown to activate PKR in response to 
TNF-/IFN- and Ang II [11].  PIF also induced an increase in activity of caspase-3 
(Fig. 6A) and caspase-8 (Fig. 6B) in myotubes, which was completely attenuated by 
AT.  The mechanism by which this effect is manifested is not known, but could be 
related to the ability of AT to chelate divalent metal ions.  Thus the inhibition by AT 
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of the increase in chymotrypsin-like enzyme activity induced by both PIF (Fig. 6C) 
and Ang II (Fig. 6D) were completely attenuated by concentrations of Zn2+ of 150M, 
or above, while the AT-induced attenuation of protein synthesis inhibition by PIF was 
also reversed by Zn2+ at concentrations of 100M or above (Fig. 6E). 
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4. Discussion 
AT is a polyanionic compound capable of chelating divalent metal ions, such 
as Ca2+ and Zn2+, which bind to phosphates P1 and P6 in the inositol ring structure 
[22].  A previous study [14] showed that AT attenuated muscle atrophy in a murine 
cachexia model and the current study suggests that it may be a potential therapy for a 
range of catabolic conditions, since it attenuates both the depression of protein 
synthesis and increase in protein degradation induced not only by PIF, but by Ang II, 
LPS and TNF-/IFN-.  Since all four agents follow the same cellular signalling 
pathway inside of the target tissue,  to induce muscle atrophy it suggests that AT 
inhibits a common step.  Since AT attenuates both the depression of protein synthesis 
and increase in protein degradation in muscle, and since activation of PKR is thought 
to be the key signal leading to both of these processes [6], it is likely that AT inhibits 
a common step leading to activation of PKR.  Indeed downstream signals from 
PKRinvolved in both the depression of protein synthesis (phosphorylation of eIF2) 
and increase in protein degradation (activation of PKC, ROS formation and nuclear 
accumulation of NF-B) are inhibited by AT.  Activation of PKR is thought to arise 
from the caspase-3/-8 cleavage of the regulatory domain leading to 
autophosphorylation [13] and the specific caspase-3 and -8 inhibitors were found to 
attenuate activation of PKR by TNF- and Ang II, as well as the increase in ROS 
formation [11]. 
The mechanism for activation of caspase-3/-8 is not known, but activation of 
caspase-3 has been suggested to be triggered by Ca2+ release from the endoplasmic 
reticulum (ER) [23].  An increase in Ca2+ concentration has also been reported to lead 
to activation of caspase-3 [24], while depletion of ER Ca2+ stores has also been shown 
to activate PKR and induce phosphorylation of eIF2 [25].  We have also shown 
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(unpublished results) that the membrane-permeable Ca2+ chelator BAPTA-AM 
attenuated the PIF-induced activation of caspase-3/-8.  These results suggest a role for 
Ca2+ in caspase activation. 
While AT can chelate Ca2+ its affinity for Zn2+ is higher.  Also the polyanionic 
nature of AT would suggest that it would not readily enter cells, and the previous 
studies suggest that mobilization of Ca2+ from the ER is involved in the activation of 
caspase-3/-8, rather than Ca2+ influx from the extracellular space.  The ability of Zn2+ 
to reverse the attenuation by AT of both the depression in protein synthesis by PIF, 
and the increased activity of the ubiquitin-proteasome pathway induced by PIF and 
Ang II, suggests a role for Zn2+ in the signalling process.  Ca2+ release from 
intracellular pools in the coloncytic cell line HT29 has been linked to extracellular 
Zn2+ through a zinc sensing receptor [26].  The Ca2+ release requires the formation of 
inositol 1,4,5-triphosphate and is zinc specific.  The Ca2+ response is mediated by a 
Gq-coupled receptor that activates the inositol phosphate pathway and was inhibited 
by phospholipase C (PLC) inhibitors [26, 27].  The Zn2+ receptor has also been 
reported to be present on prostate cancer cells [27], but it is not known if it is present 
on skeletal muscle.  If it were it would link the ability of AT to modify intracellular 
processes, even though the high negative charge would preclude its entry into the cell.  
Certainly induction of protein degradation induced by both PIF [28] and Ang II [29] 
was inhibited by both U-73122, which inhibits agonist-induced PLC activation, and 
D609, a specific inhibitor of phosphatidylcholine-specific PLC.  This suggests that the 
zinc-receptor pathway may be operating, although PLC may form another part of the 
signalling cascade. We have shown a clear inhibitory effect against muscle atrophy, 
but we have yet to clarify the specific mode of action by, for example, identifying a 
specific receptor which can be blocked by AT.  Further studies are required to 
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investigate the possible, still unidentified, zinc receptor and to explain the Ca2+ release 
from intracellular pools in muscle atrophy. 
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Figure Legends 
Fig. 1 (A) Effect of LPS alone (▲), or in the presence of AT (100M;), added 2h 
prior to LPS, on total protein degradation in murine myotubes over a 24h 
period.  (B) Western blots showing expression of the 20S proteasome -
subunits and p42 in murine myotubes 24h after addition of LPS, either alone, 
or in the presence of AT (100M).  The densitometric analysis is an average 
of 3 separate Western blots.  (C) Effect of LPS on protein synthesis in murine 
myotubes after 4h incubation, either alone (), or in the presence of AT 
(100M) ().  Differences from control are indicated as c, p<0.001, while 
differences in the presence of AT are indicated as f, p<0.001. 
Fig. 2 Effect of TNF- (50ng/ml) alone, or in combination with IFN- (10ng/ml) on 
total protein degradation in murine myotubes over a 24h period (A) and 
protein synthesis over 2h (B), either alone (), or in the presence of AT 
(100M) (), added 2h prior to the TNF-.  Differences from control are 
indicated as c, p<0.001, while differences in the presence of AT are shown as 
f, p<0.001. 
Fig. 3 Chymotrypsin-like enzyme activity in murine myotubes 24h after addition of 
PIF (A), or Ang II (B), alone (▲), or in the presence of AT () (100M).  
Western blotting of 20S proteasome -subunits (C) and p42 (D) in murine 
myotubes 24h after addition of PIF alone, or in the presence of AT (100M).  
Actin was used as a loading control.  The densitometric analysis is the average 
of three separate Western blots.  Differences from control are indicated as c, 
p<0.001, while differences in the presence of AT are shown as f, p<0.001. 
Fig. 4 Western blots showing the effect of PIF on phosphorylation of PKR (A) and 
eIF2 (B) after 4h, alone and in the presence of AT (100M) added 2h prior 
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to PIF.  The densitometric analysis represents the average of three separate 
Western blots.  Differences from control are indicated as c, p<0.001, while 
differences in the presence of AT are shown as f, p<0.001. 
Fig. 5 Western blot of cytosolic and membrane bound PKC in murine myotubes 2h 
after addition of PIF in the absence of presence of AT (100M).  (B) Dose-
response curve for ROS production in murine myotubes 30min after addition 
of PIF alone (▲), or in the presence of AT ().  The results shown are an 
average of three separate experiments, and are expressed taking basal 
fluorescence of control cells as 100%.  (C) Nuclear binding of NF-B 
determined by EMSA after treatment of myotubes for 30min with either PIF 
alone or in combination with AT.  The lane marked +ve was a positive control 
for NF-B (HeLa nuclear extract supplied by the manufacturer), while the lane 
marked –ve contains the positive control for NF-B, plus a 100-fold excess of 
unlabelled NF-B probe.  Differences from control are indicated as c, 
p<0.001, while differences in the presence of AT are shown as e, p<0.01 or f, 
p<0.001. 
Fig. 6 Activity of caspase 3 (A) and caspase 8 (B) in murine myotubes after treatment 
with PIF alone (▲), or in the presence of AT (100M) () for 1h.  The 
chymotrypsin-like enzyme activity in murine myotubes treated with either 
4.2nM PIF (C), or 0.5M Ang II (D), with or without AT (100M) for 24h is 
shown in the presence of various concentrations of ZnSO4.  (E) Protein 
synthesis in murine myotubes after 4h incubation with PIF (4.2nM), with or 
without AT (100M), and in the presence of various concentrations of ZnSO4.  
Differences from control are shown as a, p<0.05, b, p<0.01 or c, p<0.001, 
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while differences in the presence of AT are shown as f, p<0.001 and 
differences from AT alone are shown as h, p<0.01 or i, p<0.001. 
